

EliA™ Anti-IgA

Makes immunoglobulin therapy safer

Whom to test?

- Patients with IgA deficiency. Anti-IgA antibodies occur in up to 40% of them.¹
- Patients with Common Variable Immunodeficiency (CVID). Anti-IgA antibodies are detected in up to 25% of them.¹
- Celiac disease patients. Up to 3 % of them show IgA deficiency, compared to only app. 0.2 % of the general population.²

Why to test?

- Patients having anti-IgA antibodies may show severe anaphylactic reactions upon immunoglobulin therapy or blood transfusion.¹
- The frequency of transfusion reactions is as high as up to 1 in 30 in IgA deficiency, compared to only 1 in 30 000 in the general population.³

When to test?

- If immunoglobulin therapy is indicated.
- Before a blood transfusion.
- For investigation of transfusion related reactions.

Why EliA Anti-IgA?

- EliA offers a broad panel of fully automated high quality serum tests for autoimmune diseases, including 4 analytes for celiac disease (tTG IgA and IgG, deamidated gliadin IgA and IgG).
- All EliA tests can be performed on the same instruments (Phadia 100, 250, 2500 and 5000) which are designed to fit every lab size.
- A simultaneous measurement of celiac analytes and anti-IgA is easy, time-saving and gives several important information in one step.
- Delivers simple and fast results, independant of numbers of samples – best service to clinicians.



EliA Anti-IgA: No false positive results - extremely high specificity

- The performance of EliA Anti-IgA was assessed in a study using 97 samples from patients with IgA deficiency and 138 controls with normal IgA level, such as infections, hypergammaglobulinaemia, gammopathies and celiac disease (Fig. 1).
- Only IgA deficient samples showed positive results, providing the test with an optimal positive predictive value and high clinical usefulness.




Fig. 1: Clinical performance of EliA Anti-IgA

Ordering information

Product

- EliA™ Anti-IgA Well

Article number

14-5535-01

Content

24 determinations

Controls

- EliA™ Anti-IgA Positive Control 100
- EliA™ IgG/IgM/IgA Negative Control 100
- EliA™ Anti-IgA Positive Control 250
- EliA™ IgG/IgM/IgA Negative Control 250
- EliA™ Anti-IgA Positive Control 2500/5000
- EliA™ IgG/IgM/IgA Negative Control 2500/5000

83-1079-01

6 x 2 determinations

83-1042-01

6 x 2 determinations

83-1080-01

6 x 2 determinations

83-1037-01

6 x 2 determinations

83-1089-01

6 x 2 determinations

83-1074-01

6 x 2 determinations

For general reagents please see Phadia Autoimmunity Product Catalog.

References

1. Horn J et al (2006) Anti-IgA antibodies in Common Variable Immunodeficiency (CVID): Diagnostic workup and therapeutic strategy. Clin Immunol 122, 156–162
2. Kumar V et al (2002) Celiac disease and immunoglobulin A deficiency: How effective are the Serological Methods of Diagnosis? Clin Diag Lab Immunol 9, 1295-1300
3. Lilic D, Sewell WAC (2001) IgA deficiency: what we should – or should not – be doing. J Clin Pathol 54, 337-338

Phadia

Phadia GmbH, Munzinger Str. 7, D-79111 Freiburg, Germany, Tel: +49 761 47-805-0, Fax: +49 761 47-805-120, autoimmunity@phadia.com, www.phadia.com

Head office Sweden +46 18 16 50 00 Austria +43 1 270 20 20 Belgium +32 2 749 55 15 Brazil +55 11 3345 5050 Czech Republic +46 18 16 63 65 Denmark +45 70 23 33 06 Finland +358 9 8520 2560 France +33 1 6137 3430 Germany +49 761 47 805 0 Italy +39 02 64 163 411 Japan +81 3 5365 8332 Norway +47 21 67 32 80 Portugal +351 21 423 53 50 Spain +34 935 765 800 South Africa +27 11 792 6790 Switzerland +41 43 343 40 50 Taiwan +886 2 2516 0925 The Netherlands +31 30 602 37 00 United Kingdom / Ireland +44 1908 847 034 Other Countries +46 18 16 50 00